 |
 |
 |
 |
 |
 |
 |
|
|
NCCN Non-Small Cell Lung Cancer Guidelines UpdateA presentation from the NCCN 12th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care™ held in Hollywood, Florida, on March 15, 2007 Presenters David S. Ettinger, MD Mohammad Jahanzeb, MD Faculty Disclosure Statements David S. Ettinger, MD Dr. Ettinger has disclosed that he has financial interests, arrangements, or affiliations with the manufacturer of products and devices to be discussed in his presentation or who may financially support the educational activity. He has served as a paid speaker for Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech, Inc., Merck & Co., Inc., and MGI PHARMA, Inc. Additionally, he has received grant and/or research support for his roles as principal investigator for Bristol-Myers Squibb Company, Genentech, Inc., Novartis Pharmaceuticals Corporation, OSI Pharmaceuticals, Sunesis Pharmaceuticals, Inc., and sanofi-aventis U.S. Dr. Ettinger has indicated that his presentation will not include discussion of investigational or unlabeled uses of a product. Mohammad Jahanzeb, MD Dr. Jahanzeb has disclosed that he has financial interests, arrangements, or affiliations with the manufacturer of products and devices to be discussed in his presentation or who may financially support the educational activity. He receives grant or research support from Amgen Inc., Eli Lilly and Company, Genentech, Inc., GlaxoSmithKline, and sanofi-aventis U.S. Dr. Jahanzeb also serves on speakers’ bureaus for Abraxis Oncology, AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, Genentech, Inc., GlaxoSmithKline, and sanofi-aventis U.S. Dr. Jahanzeb is an advisory board member for AstraZeneca Pharmaceuticals LP, Eisai Inc., Eli Lilly and Company, Genentech, Inc., Novartis Pharmaceuticals Corporation, and Pfizer Inc. Dr. Jahanzeb has indicated that his presentation will not include discussion of investigational or unlabeled uses of a product. Program Overview This presentation will focus on the rationale behind the latest changes to the NCCN Non-Small Cell Lung Cancer Guidelines. Guidelines for screening, adjuvant therapy for stage I and II disease, management of stage III disease, and chemotherapy and targeted therapy for stage IV and recurrent disease will be discussed. Educational Objectives Following this activity, participants should be able to:
Intended Audience This educational activity is designed to meet the needs of physicians, nurses, and other clinical professionals who manage patients with cancer. Activity Instructions Continuing education credit will be awarded to participants who listen to the presentation and complete the evaluation. Participants should review the learning objectives and faculty disclosure statements prior to listening to a presentation in its entirety. You must be connected to the Internet in order to review and complete the evaluation form. A statement of credit will be electronically generated once you complete the evaluation form. To receive credit, this activity must be completed no later than May 16, 2008. There is no fee for participating in this activity. Accreditation Information Physicians The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians. NCCN designates this educational activity for a maximum of 0.75 AMA PRA Category Nurses This activity is approved for 0.8 contact hours. National Comprehensive Cancer Network is an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Approval as a provider refers to recognition of educational activities only and does not imply ANCC Commission on Accreditation or PA Nurses approval or endorsement of any product. Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity. Release date: May 16, 2007 Commercial Support Distribution supported by educational grants from Eli Lilly and Company and Genentech BioOncology/OSI Pharmaceuticals
|
|
NCCN 1st Annual Forum: Innovative Diagnostics & Therapeutics in Cancer Care™ |
|
|
